Summit to Present at the Canaccord Genuity 34th Annual Growth Conference

Accessibility: Skip TopNav

August 07, 2014 07:00 ET

Summit Therapeutics plc

Summit Therapeutics plc

Summit Corporation plc

('Summit' or the 'Company')

SUMMIT TO PRESENT COMPANY OVERVIEW AT THE CANACCORD GENUITY 34TH ANNUAL GROWTH CONFERENCE

Oxford, UK, 7 August 2014 - Summit (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection ('CDI'), announces that it will be presenting at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014, at 16:00 ET (21:00 BST). The conference will be held at the InterContinental Boston Hotel in Boston, MA.

Mr Glyn Edwards, Summit's Chief Executive Officer, will present a review of the Company's utrophin modulation programme for the treatment of the fatal muscle wasting disease DMD and he will also review Summit's selective antibiotic in development for the treatment of CDI.

A copy of the presentation will be available immediately after the event on the Investor Relations section of the Company's website, www.summitplc.com.

Summit is an Oxford, UK based drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.  Summit is quoted on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact: